Tag: <span>influenza</span>

Improving Process Economics When Developing a Vaccine Portfolio

Over the last few years, the challenges of vaccine development have created perhaps an unprecedented level of scrutiny, not just within the biotech industry, but also in the consciousness of the general public. This was certainly the case during the recent H1N1 influenza outbreak. The demand to know when a vaccine would be available, and if producers could meet the global demands consistently made front page news. The challenge of rapid and scalable manufacture is of course nothing new in biopharmaceutical development and in many respects, monoclonal antibodies are leading the way as the industry moves towards the required level of industrialization.

Read MoreImproving Process Economics When Developing a Vaccine Portfolio

Biologics Biologics Production Bioreactor Scale-Up Cell & Gene Therapy Cell Lines Fed-Batch Bioreactor Process HEK293 Mammalian Cell Culture Manufacturing Regulatory Viral Reference Materials Viral Vectors

antibody production cho cells clinical development cmo complex biologicals contract manufacturing FDA influenza novel vaccines phase 1 phase ii process economics regulatory guidelines risk-based-approach scalable manufacturing vaccine portfolio vaccines

Preparation of Haemagglutinin-lgG1 Fc Fusion Proteins in Insect Cells and Evaluation as Influenza Vaccines

ImmBio’s lead development candidate is an influenza vaccine based on the ImmunoBody® platform technology. An ImmunoBody is a fusion of a selected immuno-dominant antigen with a cell-binding domain — the Fc fragment of human IgG1. The use of recombinant Fc fusion proteins is well documented where it can help solubilize hydrophobic proteins, provide a handle for easy detection and purification, as well as improve half-life…

Read MorePreparation of Haemagglutinin-lgG1 Fc Fusion Proteins in Insect Cells and Evaluation as Influenza Vaccines

Baculovirus Expression Technology Biologics Production

BEVS influenza insect cell technology recombinant hemagglutinin proteins vaccines

Production of a Recombinant Influenza Vaccine Using the Baculovirus Expression Vector System

Influenza is a highly contagious, acute viral respiratory disease that occurs seasonally in most parts of the world. The infection resides primarily in the respiratory tract (nose, throat and bronchi), but causes both local and systemic symptoms including fever, chills, cough, headache, myalgia, sore throat, and malaise. Influenza-related pneumonia is the main complication of infection. Annual epidemics cause significant morbidity and mortality worldwide. Each year, influenza infections result in an average of 110,000 hospitalizations, approximately 20,000 of which result in death. These deaths are heavily concentrated (>90%) among persons who are at highest risk for influenza-related complications — elderly adults (over 65), children under age five, patients with pre-existing respiratory or cardiovascular disease, and women in the third trimester of pregnancy. Thus, the prevention of influenza virus infection is a major public health priority…

Read MoreProduction of a Recombinant Influenza Vaccine Using the Baculovirus Expression Vector System

Baculovirus Expression Technology Viral Vectors

BEVS influenza purification recombinant proteins transfection trivalent vaccine vaccines